Silo Pharma files a provisional patent application for SPC-15, targeting stress-induced psychiatric disorders like PTSD.
Quiver AI Summary
Silo Pharma, Inc. announced the filing of a provisional patent application for its lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders such as PTSD. The patent focuses on the chronic, combinatorial targeting of N-methyl-D-aspartate receptors and serotonin type IV receptors to enhance behavioral effects against stress-related symptoms. This filing is part of Silo's broader intellectual property strategy and builds on their partnership with Columbia University, which provides exclusive rights to develop and market SPC-15 globally. The company emphasizes this move as a reinforcement of their commitment to innovative therapies in the biopharmaceutical sector, particularly for underserved conditions like PTSD and anxiety.
Potential Positives
- Silo Pharma has filed a provisional patent application for its lead asset SPC-15, demonstrating strong commitment to developing innovative treatments for stress-induced psychiatric disorders, including PTSD.
- The provisional patent focuses on a novel approach to targeting N-methyl-D-aspartate receptors and serotonin type IV receptors, which could enhance the efficacy of treatments for stress-related conditions.
- Silo Pharma's affiliation with Columbia University for the development of SPC-15 and the exclusivity of rights to its commercialization significantly strengthens its market position and potential for future growth.
- The potential eligibility of SPC-15 for the FDA's streamlined 505(b)(2) regulatory pathway could expedite the approval process, positioning Silo for a quicker entry into the market with its innovative therapies.
Potential Negatives
- The press release highlights the company's developmental stage, suggesting it may face challenges in bringing its products to market and generating revenue.
- The use of forward-looking statements indicates uncertainty and potential volatility in the company's future performance, which may concern investors.
- The reliance on collaborations with external entities, such as Columbia University, could expose Silo Pharma to risks related to partnership effectiveness and dependency.
FAQ
What is the focus of Silo Pharma's recent patent application?
The recent patent application focuses on Silo Pharma's lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders like PTSD.
What are the key receptors targeted by SPC-15?
SPC-15 targets N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to address stress-related behaviors.
How does SPC-15 aim to benefit patients?
SPC-15 is designed to improve treatment options for patients suffering from PTSD and other stress-induced psychiatric disorders.
What regulatory pathway may expedite SPC-15's approval?
SPC-15 may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially speeding up its approval process.
Who is Silo Pharma collaborating with for research?
Silo Pharma is collaborating with Columbia University to conduct preclinical studies on SPC-15 and other innovative programs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (CEO and President) has made 3 purchases buying 7,500 shares for an estimated $6,721 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 6 institutional investors add shares of $SILO stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC added 227,006 shares (+inf%) to their portfolio in Q3 2024, for an estimated $249,706
- FINANCIAL ADVOCATES INVESTMENT MANAGEMENT removed 23,938 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $26,331
- VIRTU FINANCIAL LLC removed 16,233 shares (-38.8%) from their portfolio in Q3 2024, for an estimated $17,856
- GEODE CAPITAL MANAGEMENT, LLC added 14,582 shares (+90.1%) to their portfolio in Q3 2024, for an estimated $16,040
- CITADEL ADVISORS LLC added 14,373 shares (+inf%) to their portfolio in Q3 2024, for an estimated $15,810
- FEDERATION DES CAISSES DESJARDINS DU QUEBEC added 6,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $6,600
- TOWER RESEARCH CAPITAL LLC (TRC) removed 2,602 shares (-39.1%) from their portfolio in Q3 2024, for an estimated $2,862
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo’s commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
The provisional patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia. This filing adds to Silo’s growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally.
“Silo Pharma’s intellectual property strategy continues to be a cornerstone of our growth,” said Eric Weisblum, CEO of Silo Pharma. “We believe this latest provisional patent application reinforces our strong IP protection for SPC-15 and further positions us to deliver innovative therapies for patients with PTSD and other stress-induced disorders.”
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
